InvestorsObserver
×
News Home

Cara Therapeutics Inc (CARA) has fallen -12.43% in a Week, Should You Accumulate?

Friday, November 19, 2021 02:59 PM | InvestorsObserver Analysts

Mentioned in this article

Cara Therapeutics Inc (CARA) has fallen -12.43% in a Week, Should You Accumulate?

Cara Therapeutics Inc (CARA) is near the top in its industry group according to InvestorsObserver. CARA gets an overall rating of 51. That means it scores higher than 51 percent of stocks. Cara Therapeutics Inc gets a 78 rank in the Biotechnology industry. Biotechnology is number 84 out of 148 industries.

Overall Score - 51
CARA has an Overall Score of 51. Find out what this means to you and get the rest of the rankings on CARA!

What do These Ratings Mean?

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as “good” for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 51 means the stock is more attractive than 51 percent of stocks. This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

What's Happening With Cara Therapeutics Inc Stock Today?

Cara Therapeutics Inc (CARA) stock is trading at $14.23 as of 2:53 PM on Friday, Nov 19, a drop of -$0.21, or -1.44% from the previous closing price of $14.44. The stock has traded between $14.20 and $14.72 so far today. Volume today is less active than usual. So far 425,268 shares have traded compared to average volume of 820,163 shares. Click Here to get the full Stock Report for Cara Therapeutics Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App